Research overview
What is GHRP-2 (Pralmorelin)?
GHRP-2 is a synthetic peptide that activates growth-hormone secretagogue receptor pathways. “Pralmorelin” is a name associated with the molecule in endocrine literature. It is distinct from growth-hormone-releasing hormone analogues such as CJC-1295, and evidence for either cannot be assumed to apply to a combined preparation.
What has research examined?
A diagnostic study compared growth-hormone responses in 77 healthy subjects and 58 people with confirmed deficiency after the studied challenge, exploring test performance rather than long-term treatment. A separate randomized, blinded experiment in 19 volunteers examined food-intake and GH responses under short laboratory infusions. These endpoints show physiological activity under specific conditions, not general muscle gain, injury healing, or safe self-use.
Hormonal challenge tests and brief appetite experiments do not establish patient benefit, safety of repeated exposure, or equivalence of a supplier’s vial. FDA flags potential immunogenicity and impurity concerns for compounded injectable and nasal GHRP-2 and reports serious adverse events with causality not established. This page does not recommend a diagnostic test or any amount or use.
Research references
- A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiencyEuropean Journal of Endocrinology
- Obese subjects respond to the stimulatory effect of GHRP-2 on food intakeObesity; short controlled study
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration
Calculation boundary
The calculator performs concentration arithmetic only when a user enters a mass and liquid volume. It does not verify identity, formulation, purity, sterility, stability, compatibility, biological-unit equivalence, or whether reconstitution applies to a particular product. Do not convert IU or other biological units to mg without an authoritative, exact-product relationship.